Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 4:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 20,584 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: GIVE Clear all
Recruiting Phase 1 Interventional

A PET Imaging Agent (64Cu-DOTA-Pembrolizumab) for Determining Treatment Response Among Patients With Stage IV Non-small Cell Lung Cancer Receiving Pembrolizumab

NCT07619599
View directory record Official record
Conditions
Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Oligoprogressive Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions
Computed Tomography, Copper Cu 64-DOTA-pembrolizumab, Low Dose Radiation Therapy, Pembrolizumab, Positron Emission Tomography, Stereotactic Body Radiation Therapy
Procedure · Radiation · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 22, 2026, 4:55 AM EDT
Completed Phase 2 Interventional Results available

Irinotecan and Carboplatin as First-Line Therapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer

NCT00469898
View directory record Official record
Conditions
Lung Cancer
Interventions
Carboplatin, irinotecan hydrochloride
Drug
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
7
States / cities
Owensboro, Kentucky • Chattanooga, Tennessee • Jackson, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2012 · Synced Oct 22, 2026, 4:55 AM EDT
Completed Phase 2 Interventional Results available

Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple Myeloma

NCT01605032
View directory record Official record
Conditions
DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Busulfan, Melphalan, Bortezomib, Autologous Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation
Drug · Procedure
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years to 72 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
4
States / cities
New Brunswick, New Jersey • New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 20, 2020 · Synced Oct 22, 2026, 4:55 AM EDT
Terminated Phase 1 Interventional Results available

An Ascending Dose Study of KW-2449 in Acute Leukemias, Myelodysplastic Syndromes, and Chronic Myelogenous Leukemia

NCT00346632
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Chronic Myelogenous Leukemia
Interventions
KW-2449
Drug
Lead sponsor
Kyowa Kirin, Inc.
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
4
States / cities
Baltimore, Maryland • Princeton, New Jersey • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 17, 2024 · Synced Oct 22, 2026, 4:55 AM EDT
Withdrawn Phase 2 Interventional

Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations

NCT02263898
View directory record Official record
Conditions
Recurrent Melanoma, Stage IV Melanoma
Interventions
Raf kinase inhibitor LGX818, binimetinib, laboratory biomarker analysis
Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Oct 22, 2026, 4:55 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Hormonal Mechanisms of Sleep Restriction - Axis Study

NCT03142893
View directory record Official record
Conditions
Sleep Restriction
Interventions
Ketoconazole Pill, Ganirelix, Dexamethasone, Dexamethasone Injection, Cosyntropin Injectable Product, Recombinant Human Luteinizing Hormone, Hydrocortisone Injection, Gonadorelin, Corticorelin, Placebo oral capsule, Saline Solution, Saline Solution for Injection
Drug
Lead sponsor
Peter y. Liu
Other
Eligibility
22 Years to 45 Years · Male only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2026
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 22, 2026, 4:55 AM EDT
Completed Not applicable Interventional

Study 1: Social Engage Coaching R61 Phase

NCT05745493
View directory record Official record
Conditions
Social Isolation, Loneliness, Suicide Ideation, Quality of Life
Interventions
Social Engage Coaching (S-ENG)
Behavioral
Lead sponsor
University of Rochester
Other
Eligibility
60 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 22, 2026, 4:55 AM EDT
Recruiting Early Phase 1 Interventional

HMCT/CT2401: Abatacept GVHD Prophylaxis Following Omidubicel HCT

NCT06731504
View directory record Official record
Conditions
Hematologic Malignancy
Interventions
Abatacept
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Oct 22, 2026, 4:55 AM EDT
Not listed Not applicable Interventional

Value For Veterans (V4V)

NCT05026684
View directory record Official record
Conditions
Delivery of Health Care
Interventions
Personalized cost handout
Other
Lead sponsor
VA Ann Arbor Healthcare System
Federal
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 29, 2022 · Synced Oct 22, 2026, 4:55 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Lybrido for Female Sexual Dysfunction

NCT01432665
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
Placebo, Sildenafil, Testosterone
Drug
Lead sponsor
Emotional Brain NY Inc.
Industry
Eligibility
21 Years to 70 Years · Female only
Enrollment
196 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
14
States / cities
San Diego, California • Washington D.C., District of Columbia • Brooksville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2013 · Synced Oct 22, 2026, 4:55 AM EDT
Completed Not applicable Interventional Results available

In Person and mHealth Coping Skills Training for Symptom Management and Steps in Stem Cell Transplant Patients

NCT03859765
View directory record Official record
Conditions
Stem Cell Transplant
Interventions
HCT Symptoms and Steps
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 22, 2024 · Synced Oct 22, 2026, 4:55 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Study of Pemetrexed Plus Gemcitabine for Metastatic/Recurrent Head and Neck Cancer (HNSCC)

NCT00589667
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Pemetrexed plus Gemcitabine
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 2, 2014 · Synced Oct 22, 2026, 4:55 AM EDT
Completed Phase 2 Interventional Results available

Contrast-Enhanced Ultrasound for the Prediction of Bile Duct Cancer Response to Radioembolization Treatment

NCT05328167
View directory record Official record
Conditions
Intrahepatic Cholangiocarcinoma
Interventions
Perflutren Protein-Type A Microspheres, Contrast-Enhanced Ultrasound
Drug · Procedure
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Oct 22, 2026, 4:55 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Tolerability of Pirfenidone in Acute Pancreatitis

NCT05350371
View directory record Official record
Conditions
Pancreatitis, Acute
Interventions
Pirfenidone Oral Tablet, Placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 85 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Birmingham, Alabama • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 22, 2026, 4:55 AM EDT
Terminated Phase 2 Interventional Results available

Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing Surgery

NCT04370509
View directory record Official record
Conditions
Metastatic Clear Cell Renal Cell Carcinoma, Recurrent Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Clear Cell Renal Cell Carcinoma
Interventions
Axitinib (VEGF-TKI), Cytoreductive Nephrectomy (CN), Metastasectomy (MET), Pembrolizumab
Drug · Procedure · Biological
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Oct 22, 2026, 4:55 AM EDT
Completed Phase 4 Interventional Results available

Sitagliptin in Non-Diabetic Patients Undergoing General Surgery

NCT02741687
View directory record Official record
Conditions
Hyperglycemia
Interventions
Sitagliptin, Placebo, Supplemental insulin (insulin lispro), Supplemental insulin (insulin aspart), Long acting basal insulin (insulin detemir), Long acting basal insulin (insulin glargine)
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 27, 2018 · Synced Oct 22, 2026, 4:55 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome

NCT03047993
View directory record Official record
Conditions
Acute Myeloid Leukemia With Multilineage Dysplasia, Blasts 20-30 Percent of Bone Marrow Nucleated Cells, Blasts 20-30 Percent of Peripheral Blood White Cells, Chronic Myelomonocytic Leukemia, High Risk Myelodysplastic Syndrome, IPSS Risk Category Intermediate-2, Myelodysplastic Syndrome
Interventions
Azacitidine, Glutaminase Inhibitor CB-839
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 14, 2024 · Synced Oct 22, 2026, 4:55 AM EDT
Terminated Phase 3 Interventional Results available

Resuscitation Outcomes Consortium (ROC) Prehospital Resuscitation Using an Impedance Valve

NCT00394706
View directory record Official record
Conditions
Heart Arrest
Interventions
Impedance Threshold Device (ITD), Sham ITD, Analyze early, Analyze later
Device · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
11,738 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
7
States / cities
Birmingham, Alabama • San Diego, California • Portland, Oregon + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Oct 22, 2026, 4:55 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Randomized Single-Blinded Study to Evaluate Safety and Immunogenicity of Recombinant Plague Vaccine With and Without Adjuvant

NCT01122784
View directory record Official record
Conditions
Plague Vaccine
Interventions
rF1V vaccine (with Adjuvant), rF1V vaccine (without Adjuvant)
Biological
Lead sponsor
DynPort Vaccine Company LLC, A GDIT Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
402 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
11
States / cities
San Francisco, California • Santa Ana, California • Lenexa, Kansas + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2020 · Synced Oct 22, 2026, 4:55 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Interferon-Gamma 1b in Patients With Candidemia

NCT04979052
View directory record Official record
Conditions
Candidemia
Interventions
Interferon Gamma-1B
Drug
Lead sponsor
Radboud University Medical Center
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 22, 2026, 4:55 AM EDT
Recruiting Phase 2 Interventional

Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer

NCT07407647
View directory record Official record
Conditions
Anal Carcinoma, Cervical Carcinoma, Malignant Female Reproductive System Neoplasm, Rectal Carcinoma, Vaginal Carcinoma, Vulvar Carcinoma
Interventions
Biospecimen Collection, Prasterone, Survey Administration
Procedure · Drug · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
50 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 22, 2026, 4:55 AM EDT
Active, not recruiting Phase 2 Interventional

A Trial of Vigil for Participants With Ovarian Cancer

NCT02346747
View directory record Official record
Conditions
Ovarian Cancer, Ovarian Neoplasms
Interventions
Vigil, Placebo
Biological · Other
Lead sponsor
Gradalis, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
26
States / cities
Mobile, Alabama • Irvine, California • San Francisco, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 22, 2026, 4:55 AM EDT
Completed Not applicable Interventional

Adaptation of Dialectical Behavior Therapy Skills-Groups for Individuals With Suicidal Ideation and Depression

NCT01441258
View directory record Official record
Conditions
Suicidal Ideation, Major Depressive Disorder
Interventions
Dialectical Behavior Therapy Skills (DBT-S) Groups, Wait List-Treatment as Usual, No intervention-treatment as usual
Behavioral
Lead sponsor
Maurizio Fava, MD
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 8, 2015 · Synced Oct 22, 2026, 4:55 AM EDT
Completed Early Phase 1 Interventional Results available

A Pilot Study of Trans Arterial Chemoembolization (TACE), Followed by Stereotactic Radiation Therapy (SBRT) for Patients With Hepatocellular Carcinoma

NCT01247298
View directory record Official record
Conditions
Hepatocellular Carcinoma (HCC)
Interventions
Stereotactic Body Radiation Therapy (SBRT)
Combination Product
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 21, 2017 · Synced Oct 22, 2026, 4:55 AM EDT